ARS Pharmaceuticals, Inc. 8-K

What Happened

• ARS Pharmaceuticals (SPRY) announced on May 12, 2026 that the Board, based in part on CEO Richard Lowenthal’s recommendation, has appointed Donn Casale as President effective when he begins employment (expected June 1, 2026). Mr. Casale, age 53, has over 25 years in biopharma (Dynavax 2017–May 2026, including CCO since Jan 2023; Depomed 2014–2017; Merck 2000–2014).
• The company entered into an employment agreement providing compensation and equity awards; the full agreement is filed as Exhibit 10.1 to the 8-K.

Key Details

• Start date (expected): June 1, 2026.
• Base salary: $575,000 per year.
• Annual discretionary bonus target: 45% of base salary.
• Equity grant: stock option with an economic value determined by dividing $6,000,000 by a price per share (using a modified Black‑Scholes method); exercise price = Grant Date Closing Price. Vesting: 25% after 1 year, then monthly over the next 36 months (subject to continued employment).
• Mr. Casale will sign the company’s standard indemnification agreement and a participation agreement for the Change in Control and Severance Benefit Plan (C‑suite level benefits; accelerated vesting limited during the first year in certain change‑in‑control cases).

Why It Matters

• Leadership: The appointment fills the President role with a commercial leader who has recent C‑suite commercial experience, which could support ARS’s commercial and go‑forward strategy.
• Compensation and dilution: The agreement includes a meaningful cash salary and a multi‑million‑dollar equity grant (structured as options), which could affect future share-based compensation expense and potential dilution as options vest/exercise.
• Corporate governance: The participation in the company’s change‑in‑control plan and standard indemnification are material terms investors monitor for executive incentives and potential severance liabilities.